“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units

Spasticity, a common complication of neurological diseases, can lead to significant complications such as movement impairment and pain. Botulinum toxin type A (BTX-A) is used to reduce muscle tone by modulating the release of acetylcholine. This study focuses on the effectiveness and safety of IncobotulinumtoxinA, exploring a range of doses from 100 to 1000 units to manage spasticity based on individual patient needs. The aim is to balance reducing excessive muscle tone while preserving remaining motor function. The study emphasizes 'appropriate treatment' over standardized dosages, tailoring treatment plans to each patient's specific needs as determined through clinical and instrumental evaluations of their spasticity.

• 1
  IncobotulinumtoxinA demonstrates a wide therapeutic window, allowing for safe and effective spasticity management with doses ranging from 100 to 1000 units, tailored to individual patient needs.
• 2
  Increasing the dosage of IncobotulinumtoxinA, when clinically indicated, resulted in improved spasticity control and functional outcomes, as measured by clinical and instrumental assessments.
• 3
  Long-term treatment with IncobotulinumtoxinA (over two years) did not lead to a reduction in clinical efficacy, suggesting a low risk of antibody formation against the toxin.